|Company Name||NeoGenomics, Inc.|
On March 28, 2022, after the market closed, NeoGenomics announced that its Chief Executive Officer, Mark Mallon, had resigned, less than a year after accepting the position. The Company also stated that revenue for first quarter 2022 would be “below the low end of its prior guidance of $118 - $120 million” and withdrew its fiscal 2022 guidance.
On this news, NeoGenomics’ stock fell $5.30, or 29.8%, to close at $12.49 per share on March 29, 2022, thereby injuring investors.
Submit Your Information
If you suffered a loss on your NeoGenomics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.